The FDA announced approval of secukinumab, an IL-17 inhibitor, for the treatment of moderate to severe plaque psoriasis in patients aged 6 years and older.
The approved dosing is 75 mg or 150 mg, dependent on the child’s weight at dosing...
The FDA announced approval of secukinumab, an IL-17 inhibitor, for the treatment of moderate to severe plaque psoriasis in patients aged 6 years and older.
The approved dosing is 75 mg or 150 mg, dependent on the child’s weight at dosing...
The FDA announced approval of...